Canada Markets open in 1 hr 13 mins

BioVaxys Technology Corp. (BVAXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2034-0.0173 (-7.83%)
At close: 3:57PM EST

BioVaxys Technology Corp.

905 West Pender Street
Suite 503
Vancouver, BC V6C 1L6
Canada
604 262 8835
http://www.biovaxys.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. James Christopher PassinCo-Founder, CEO & Director8.08kN/A1972
Mr. Kenneth E. KovanCo-Founder, Pres & COO16.3kN/A1963
Mr. Lachlan McLeod CPACFO & Corp. Sec.12.12kN/A1988
Dr. David BerdCo-Founder & Chief Medical OfficerN/AN/A1943
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor antigen vaccine for ovarian cancer, as well as and Covid-T, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and Covid-T; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its Covid-T immunodiagnostic. The company is headquartered in Vancouver, Canada.

Corporate Governance

BioVaxys Technology Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.